Overslaan en naar de inhoud gaan
Vitaflo VIA Education Portal
  • PHENYLKETONURIA - INFANTS
  • PHENYLKETONURIA - CHILDREN
  • PHENYLKETONURIA - ADOLESCENTS AND ADULTS
  • PHENYLKETONURIA - MATERNAL
  • PHENYLKETONURIA - GMP
  • RARE DISORDERS OF PROTEIN METABOLISM
  • LIPID DISORDERS
  • GLYCOGEN STORAGE DISEASE
  • DRUG RESISTANT EPILEPSY - KETOGENIC DIET
  • DRUG RESISTANT EPILEPSY - K.VITA
  • KIDNEY DISEASE - PAEDIATRIC
  • KIDNEY DISEASE – ADULTS
  • NUTRITION SUPPORT
  • MULTILINGUAL RESOURCES
  • Product calculators and tools
  • CPD REFLECTION TOOL
  • MCT CALCULATOR - LIPID DISORDERS
  • PKU TRIO CALCULATOR
  • KETOGENIC DIET NUTRITIONAL INTAKE TOOL
  • MPKU & LACTATION INTAKE ASSESSMENT
EVENTS
COURSES
BLOGS
Registreren Inloggen

Kruimelpad

  1. Home

Meertalige bronnen

Hier vindt u bronnen in verschillende Europese talen, evenals landspecifieke webinaropnamen die diverse stoornisgebieden behandelen.

Kies hieronder uw taal om de inhoud te verkennen.

Flag banner

Choose Page Language

This will display this page in the selected language.

  • Dutch
  • English
  • Français
  • Deutsch
  • Italiano
  • - Elk -
  • Flag of nl
  • Flag of fr
  • Flag of de
  • Flag of it
Black signpost with white arrows pointing in different directions
Praktische Gids

Keyo®

01/05/2017

Paginering

  • Vorige pagina ‹ Previous
  • Pagina 2
  • DISORDER AREAS
  • Phenylketonuria - Infants
  • Phenylketonuria - Children
  • Phenylketonuria - Adolescents and Adults
  • Phenylketonuria - Maternal
  • Phenylketonuria - GMP
  • Rare Disorders of Protein Metabolism
  • Lipid Disorders
  • Glycogen Storage Disease
  • Drug Resistant Epilepsy - Ketogenic Diet
  • Drug Resistant Epilepsy - K.Vita
  • Kidney Disease - Paediatric
  • Kidney Disease - Adults
  • Nutrition Support
  • Multilingual Resources
  • TOOLS
  • CPD Reflection Tool
  • MCT Calculator
  • PKU Trio Calculator
  • mPKU & Lactation Intake Assessment
  • BLOG
  • Blogs
  • CONTACT
  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Accessibility Statement
  • Follow us on LinkedIn